Table 1.
Immunization against mouse gp75
| Source of gp75 | Adjuvant | No of injections | Route | Dose | Ab/CTL Response |
|---|---|---|---|---|---|
| B16 melanoma | None | 1 | s.c., i.v. | 50, 00 | No response |
| Irradiated B16 | None | 5 | i.p. | 8 × 106 | No response |
| Irradiated B16 | F, D, Q | 5 | i.p. | 8 × 106 | No response |
| 3.27 tx | None | 5 | i.p., s.c. | 8 × 106 | No response |
| 3.27 tx | F, D, Q | 5 | i.p., s.c. | 8 × 106 | No response |
| TIB88/gp75 tx | F | 4 | i.p., s.c. | 5 × 106 | No response |
| B16–IFN-γ | None | 5 | s.c., i.v. | 8 × 106 | No response |
| B16–IL-2 | None | 5 | s.c., i.v. | 8 × 106 | No response |
| B16–IL-2/IFNγ | None | 5 | s.c., i.v. | 8 × 106 | No response |
| B16–GM-CSF | None | 5 | s.c., i.v. | 8 × 106 | No response |
| Purified gp75 | F, Q | 5 | s.c., i.v. | 10 μg | No response |
| gp75 peptides | F, Q | 5 | id | 100 μg | No response |
C57BL/6 mice were immunized with gp75 sources as indicated and described in the Materials and Methods. Dose refers to individual dose per injection, either number of cells per injection or amount of protein or peptide. One week following the last immunization, sera were tested by immunoprecipitation and Western blots against lysates of syngeneic B16F10 melanoma and ELISA for antibodies (Ab) to gp75 and splenocytes were tested for CTL responses as described. Under adjuvant, F = Freund’s adjuvant; D = Detox adjuvant; and Q = QS21 adjuvant. No of injections = number of immunizations at 7- to 14-day intervals. B16–IFN-γ, –IL-2 (interleukin 2), and –GM-CSF refer to B16F16 melanoma cells expressing the designated cytokine. tx, Transfectant. 3.27 are B78 H.1 melanoma cells transfected with gp75, and TIB88/gp75 are syngeneic fibroblasts transfected with gp75.